A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)

Translated title of the contribution: Effects of Doxium 500® in gestational hypertension

P. Tamas, I. Szabó, J. Szekely, T. Csermely, F. T. Prievara, L. Nemeth, I. Szemerei

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Doxium (calcium dobesilate) can favourably influence the microcirculation in different pathological conditions. To test its potential effects in pregnancies complicated with pregnancy-induced hypertension (PIH) or pre-eclampsia (PE) a double-blind, placebo-controlled study was carried out. Enrolled 23 patients (gest. age 34 ≤ week) with gestational hypertension (GH) [mean arterial pressure (MAP) > 105 mmHg] daily took 2000 mg of Doxium or placebo onward until delivery. Retrospective analysis revealed that 2 patients in the placebo group (PG) and 8 in the active group (AG) had PE [GH + proteinuria (PU) ≤ 0.5 g/day] at the time of enrollment. Twelve patients received placebo for 52.6 days, and 11 patients took drugs for 57.0 days on average. MAP and PU were determined daily, parameters of renal function, haemorheology and some plasma components were weekly measured. The data collected at the start and at the end of treatment were compared. The biophysical profile of the fetuses, conditions of the deliveries, and the neonatal period were also recorded. The MAP (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mmHg in the AG (p <0.001), meanwhile in the PG it slightly increased. PU was higher in the AG at the start of medication, however, no significant changes of this parameter were detected throughout the study. Although values of fibronectin decreased significantly in both groups, it was more pronounced in the AG (23.8% vs. 9.4%). Changes of platelet count, plasma and blood viscosity were favourable in the AG and worsened in the PG but none of the alterations were statistically significant. No marked differences were found between the two groups regarding fetal wellbeing, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. Doxium seems to be an effective and safe drug in the management of GH. However, further studies are needed to confirm our preliminary results and evaluate its effects on perinatal outcome.

Original languageHungarian
Pages (from-to)181-187
Number of pages7
JournalMagyar Noorvosok Lapja
Volume60
Issue number3
Publication statusPublished - 1997

Fingerprint

Calcium Dobesilate
Pregnancy Induced Hypertension
Placebos
Proteinuria
Arterial Pressure
Pre-Eclampsia
Hemorheology
Blood Viscosity
Microcirculation
Platelet Count
Fibronectins
Pharmaceutical Preparations
Fetus
Mothers
Kidney
Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Tamas, P., Szabó, I., Szekely, J., Csermely, T., Prievara, F. T., Nemeth, L., & Szemerei, I. (1997). A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany). Magyar Noorvosok Lapja, 60(3), 181-187.

A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany). / Tamas, P.; Szabó, I.; Szekely, J.; Csermely, T.; Prievara, F. T.; Nemeth, L.; Szemerei, I.

In: Magyar Noorvosok Lapja, Vol. 60, No. 3, 1997, p. 181-187.

Research output: Contribution to journalArticle

Tamas, P, Szabó, I, Szekely, J, Csermely, T, Prievara, FT, Nemeth, L & Szemerei, I 1997, 'A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)', Magyar Noorvosok Lapja, vol. 60, no. 3, pp. 181-187.
Tamas, P. ; Szabó, I. ; Szekely, J. ; Csermely, T. ; Prievara, F. T. ; Nemeth, L. ; Szemerei, I. / A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany). In: Magyar Noorvosok Lapja. 1997 ; Vol. 60, No. 3. pp. 181-187.
@article{7569b59a6d7b44bf9c972fe287986591,
title = "A Doxium 500{\circledR} hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)",
abstract = "Doxium (calcium dobesilate) can favourably influence the microcirculation in different pathological conditions. To test its potential effects in pregnancies complicated with pregnancy-induced hypertension (PIH) or pre-eclampsia (PE) a double-blind, placebo-controlled study was carried out. Enrolled 23 patients (gest. age 34 ≤ week) with gestational hypertension (GH) [mean arterial pressure (MAP) > 105 mmHg] daily took 2000 mg of Doxium or placebo onward until delivery. Retrospective analysis revealed that 2 patients in the placebo group (PG) and 8 in the active group (AG) had PE [GH + proteinuria (PU) ≤ 0.5 g/day] at the time of enrollment. Twelve patients received placebo for 52.6 days, and 11 patients took drugs for 57.0 days on average. MAP and PU were determined daily, parameters of renal function, haemorheology and some plasma components were weekly measured. The data collected at the start and at the end of treatment were compared. The biophysical profile of the fetuses, conditions of the deliveries, and the neonatal period were also recorded. The MAP (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mmHg in the AG (p <0.001), meanwhile in the PG it slightly increased. PU was higher in the AG at the start of medication, however, no significant changes of this parameter were detected throughout the study. Although values of fibronectin decreased significantly in both groups, it was more pronounced in the AG (23.8{\%} vs. 9.4{\%}). Changes of platelet count, plasma and blood viscosity were favourable in the AG and worsened in the PG but none of the alterations were statistically significant. No marked differences were found between the two groups regarding fetal wellbeing, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. Doxium seems to be an effective and safe drug in the management of GH. However, further studies are needed to confirm our preliminary results and evaluate its effects on perinatal outcome.",
keywords = "Doxium, gestational hypertension, treatment",
author = "P. Tamas and I. Szab{\'o} and J. Szekely and T. Csermely and Prievara, {F. T.} and L. Nemeth and I. Szemerei",
year = "1997",
language = "Hungarian",
volume = "60",
pages = "181--187",
journal = "Magyar Noorvosok Lapja",
issn = "0025-021X",
publisher = "Magyar Noovos Tarsasag",
number = "3",

}

TY - JOUR

T1 - A Doxium 500® hatasanak vizsgalata terhessegi hypertoniaban (kettos vak, placebo-kontrollalt tanulmany)

AU - Tamas, P.

AU - Szabó, I.

AU - Szekely, J.

AU - Csermely, T.

AU - Prievara, F. T.

AU - Nemeth, L.

AU - Szemerei, I.

PY - 1997

Y1 - 1997

N2 - Doxium (calcium dobesilate) can favourably influence the microcirculation in different pathological conditions. To test its potential effects in pregnancies complicated with pregnancy-induced hypertension (PIH) or pre-eclampsia (PE) a double-blind, placebo-controlled study was carried out. Enrolled 23 patients (gest. age 34 ≤ week) with gestational hypertension (GH) [mean arterial pressure (MAP) > 105 mmHg] daily took 2000 mg of Doxium or placebo onward until delivery. Retrospective analysis revealed that 2 patients in the placebo group (PG) and 8 in the active group (AG) had PE [GH + proteinuria (PU) ≤ 0.5 g/day] at the time of enrollment. Twelve patients received placebo for 52.6 days, and 11 patients took drugs for 57.0 days on average. MAP and PU were determined daily, parameters of renal function, haemorheology and some plasma components were weekly measured. The data collected at the start and at the end of treatment were compared. The biophysical profile of the fetuses, conditions of the deliveries, and the neonatal period were also recorded. The MAP (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mmHg in the AG (p <0.001), meanwhile in the PG it slightly increased. PU was higher in the AG at the start of medication, however, no significant changes of this parameter were detected throughout the study. Although values of fibronectin decreased significantly in both groups, it was more pronounced in the AG (23.8% vs. 9.4%). Changes of platelet count, plasma and blood viscosity were favourable in the AG and worsened in the PG but none of the alterations were statistically significant. No marked differences were found between the two groups regarding fetal wellbeing, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. Doxium seems to be an effective and safe drug in the management of GH. However, further studies are needed to confirm our preliminary results and evaluate its effects on perinatal outcome.

AB - Doxium (calcium dobesilate) can favourably influence the microcirculation in different pathological conditions. To test its potential effects in pregnancies complicated with pregnancy-induced hypertension (PIH) or pre-eclampsia (PE) a double-blind, placebo-controlled study was carried out. Enrolled 23 patients (gest. age 34 ≤ week) with gestational hypertension (GH) [mean arterial pressure (MAP) > 105 mmHg] daily took 2000 mg of Doxium or placebo onward until delivery. Retrospective analysis revealed that 2 patients in the placebo group (PG) and 8 in the active group (AG) had PE [GH + proteinuria (PU) ≤ 0.5 g/day] at the time of enrollment. Twelve patients received placebo for 52.6 days, and 11 patients took drugs for 57.0 days on average. MAP and PU were determined daily, parameters of renal function, haemorheology and some plasma components were weekly measured. The data collected at the start and at the end of treatment were compared. The biophysical profile of the fetuses, conditions of the deliveries, and the neonatal period were also recorded. The MAP (mean ± SD) significantly decreased from 118 ± 7 to 99 ± 9 mmHg in the AG (p <0.001), meanwhile in the PG it slightly increased. PU was higher in the AG at the start of medication, however, no significant changes of this parameter were detected throughout the study. Although values of fibronectin decreased significantly in both groups, it was more pronounced in the AG (23.8% vs. 9.4%). Changes of platelet count, plasma and blood viscosity were favourable in the AG and worsened in the PG but none of the alterations were statistically significant. No marked differences were found between the two groups regarding fetal wellbeing, courses of deliveries, and the neonatal period. Neither maternal nor fetal/neonatal side effects were noticed. Doxium seems to be an effective and safe drug in the management of GH. However, further studies are needed to confirm our preliminary results and evaluate its effects on perinatal outcome.

KW - Doxium

KW - gestational hypertension

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0030941782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030941782&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 181

EP - 187

JO - Magyar Noorvosok Lapja

JF - Magyar Noorvosok Lapja

SN - 0025-021X

IS - 3

ER -